Mark Milton

2.0k total citations · 1 hit paper
36 papers, 1.2k citations indexed

About

Mark Milton is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mark Milton has authored 36 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Molecular Biology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mark Milton's work include Monoclonal and Polyclonal Antibodies Research (7 papers), CAR-T cell therapy research (7 papers) and Drug Transport and Resistance Mechanisms (7 papers). Mark Milton is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), CAR-T cell therapy research (7 papers) and Drug Transport and Resistance Mechanisms (7 papers). Mark Milton collaborates with scholars based in United States, Switzerland and United Kingdom. Mark Milton's co-authors include Patrick Muller, Christopher Horvath, Cindy Q. Xia, Liang‐Shang Gan, Shenghua Wen, Peter J. Worland, Matthew D. Silva, Michael D. Henry, Sudeep Chandra and Jennifer Sims and has published in prestigious journals such as Nature reviews. Immunology, Nature Reviews Drug Discovery and Cancer Research.

In The Last Decade

Mark Milton

33 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The determination and interpretation of the therapeutic index in drug development

2012 400 citations Patrick Muller, Mark Milton profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Milton United States	18	516	381	212	210	141	36	1.2k
Ziping Yang United States	21	944 1.8×	455 1.2×	194 0.9×	218 1.0×	185 1.3×	45	1.7k
Amrita V. Kamath United States	24	631 1.2×	641 1.7×	202 1.0×	451 2.1×	93 0.7×	58	1.6k
Yue Zhou China	25	1.0k 2.0×	471 1.2×	293 1.4×	103 0.5×	118 0.8×	120	1.9k
Erich Gebhart Germany	23	1.2k 2.3×	459 1.2×	137 0.6×	99 0.5×	136 1.0×	63	2.1k
Pascale Anderle Switzerland	24	935 1.8×	889 2.3×	172 0.8×	45 0.2×	80 0.6×	28	1.8k
Timothy K. Hart United States	19	903 1.8×	174 0.5×	302 1.4×	103 0.5×	47 0.3×	42	1.9k
Tove Tuntland United States	25	732 1.4×	214 0.6×	131 0.6×	71 0.3×	75 0.5×	39	1.7k
Scott Heyward United States	22	738 1.4×	367 1.0×	119 0.6×	122 0.6×	378 2.7×	48	1.7k
Neil French United Kingdom	19	592 1.1×	176 0.5×	222 1.0×	76 0.4×	427 3.0×	37	1.6k
Lawrence W. Anderson United States	23	728 1.4×	351 0.9×	46 0.2×	84 0.4×	119 0.8×	57	1.5k

Countries citing papers authored by Mark Milton

Since Specialization

Citations

This map shows the geographic impact of Mark Milton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Milton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Milton more than expected).

Fields of papers citing papers by Mark Milton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Milton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Milton. The network helps show where Mark Milton may publish in the future.

Co-authorship network of co-authors of Mark Milton

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Milton. A scholar is included among the top collaborators of Mark Milton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Milton. Mark Milton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Braun, Manuela, Claudia Lange, Philipp Schatz, et al.. (2024). Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirements. Molecular Therapy — Methods & Clinical Development. 32(1). 101217–101217. 11 indexed citations

Milton, Mark, et al.. (2023). Identification and enrichment of a UV-induced degradant of Anagrelide drug substance. Journal of Pharmaceutical and Biomedical Analysis. 229. 115352–115352.

Gorovits, Boris, George Buchlis, Michele Fiscella, et al.. (2023). Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy. The AAPS Journal. 25(3). 47–47. 18 indexed citations

Tukov, F, Keith G. Mansfield, Mark Milton, et al.. (2022). Single-Dose Intrathecal Dorsal Root Ganglia Toxicity of Onasemnogene Abeparvovec in Cynomolgus Monkeys. Human Gene Therapy. 33(13-14). 740–756. 28 indexed citations

Gorovits, Boris, George Buchlis, Travis Harrison, et al.. (2021). Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays. The AAPS Journal. 23(6). 108–108. 32 indexed citations

Gorovits, Boris, Michele Fiscella, Eugen Koren, et al.. (2020). Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays. The AAPS Journal. 22(2). 24–24. 35 indexed citations

Zafra, Christina L. Zuch de, Vito G. Sasseville, Steven S. Matsumoto, et al.. (2017). Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics. Regulatory Toxicology and Pharmacology. 86. 221–230. 25 indexed citations

Milton, Mark, et al.. (2016). Metabolism, Excretion and Pharmacokinetics of MLN3897, a CCR1 Antagonist, in Humans. Drug Metabolism Letters. 10(1). 22–37.

Julius, Ulrich, Mark Milton, Daniel J. Rader, et al.. (2015). Effects of lipoprotein apheresis on PCSK9 levels. Atherosclerosis Supplements. 18. 180–186. 17 indexed citations

10.

Brennan, Frank R., Andreas Baumann, Lolke de Haan, et al.. (2015). Nonclinical safety testing of biopharmaceuticals – Addressing current challenges of these novel and emerging therapies. Regulatory Toxicology and Pharmacology. 73(1). 265–275. 13 indexed citations

11.

Milton, Mark, et al.. (2014). Anti-C5 mAb: In Vivo Effects Following Intravitreal Administration to Cynomolgus Monkeys. Investigative Ophthalmology & Visual Science. 55(13). 1176–1176.

12.

Horvath, Christopher, Laura Andrews, Andreas Baumann, et al.. (2012). Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial. Nature reviews. Immunology. 12(10). 740–740. 27 indexed citations

13.

Muller, Patrick, Mark Milton, Peter Lloyd, Jennifer Sims, & Frank R. Brennan. (2009). The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Current Opinion in Biotechnology. 20(6). 722–729. 88 indexed citations

14.

Horvath, Christopher & Mark Milton. (2009). The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event?. Toxicologic Pathology. 37(3). 372–383. 37 indexed citations

15.

Xia, Cindy Q., Mark Milton, & Liang‐Shang Gan. (2007). Evaluation of Drug-Transporter Interactions Using In Vitro and In Vivo Models. Current Drug Metabolism. 8(4). 341–363. 71 indexed citations

16.

Henry, Michael D., Shenghua Wen, Matthew D. Silva, et al.. (2004). A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody–Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer. Cancer Research. 64(21). 7995–8001. 124 indexed citations

17.

Zhang, Ji Y., et al.. (2004). Disposition and Pharmacokinetics of L-N6-(1-Iminoethyl)Lysine-5-Tetrazole-Amide, a Selective iNOS Inhibitor, in Rats. Journal of Pharmaceutical Sciences. 93(5). 1229–1240. 7 indexed citations

18.

Milton, Mark, Maria Beconi, Mei‐Ping Chang, et al.. (2003). Pharmacokinetics, metabolism and excretion of an inhibitor of inducible nitric oxide synthase, L-NIL-TA, in dog. Xenobiotica. 33(11). 1159–1171. 2 indexed citations

19.

Gibson, G. Gordon, Mark Milton, & Cliff Elcombe. (1990). Induction of cytochrome P-450 IVA 1-mediated fatty acid hydroxylation: relevance to peroxisome proliferation. Biochemical Society Transactions. 18(1). 97–99. 7 indexed citations

20.

Milton, Mark, et al.. (1988). Lack of evidence for a hepatic peroxisome proliferator receptor and an explanation for the binding of hypolipidaemic drugs to liver homogenates. Biochemical Pharmacology. 37(5). 793–798. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact